Eloxx Pharmaceuticals Inc (ELOX) - Financial and Strategic SWOT Analysis Review

August 2021 | 67 pages | ID: E052548E103EN
GlobalData

Abstracts

Eloxx Pharmaceuticals Inc (ELOX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Eloxx Pharmaceuticals Inc (Eloxx) formerly known as Sevion Therapeutics Inc, is a biopharmaceutical company that develops novel RNA-modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. The company lead product candidate, ELX-02, in early stage of clinical development for treatment of cystic fibrosis. Its preclinical candidate consists of novel ERSG drug candidates for treatment of autosomal dominant polycystic kidney disease (ADPKD) and usher syndrome. The company has subsidiary in Isreal. Eloxx is headquartered in Waltham, Massachusetts, the US.

Eloxx Pharmaceuticals Inc Key Recent Developments

Aug 16,2021: Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update
May 06,2021: Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update
Mar 11,2021: Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update
Mar 04,2021: Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021
Nov 05,2020: Eloxx Pharmaceuticals reports third quarter 2020 financial and operating results and provides business update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Eloxx Pharmaceuticals Inc - Key Facts
Eloxx Pharmaceuticals Inc - Key Employees
Eloxx Pharmaceuticals Inc - Key Employee Biographies
Eloxx Pharmaceuticals Inc - Major Products and Services
Eloxx Pharmaceuticals Inc - History
Eloxx Pharmaceuticals Inc - Company Statement
Eloxx Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Eloxx Pharmaceuticals Inc - Business Description
R&D Overview
Eloxx Pharmaceuticals Inc - Corporate Strategy
Eloxx Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Eloxx Pharmaceuticals Inc - Strengths
Eloxx Pharmaceuticals Inc - Weaknesses
Eloxx Pharmaceuticals Inc - Opportunities
Eloxx Pharmaceuticals Inc - Threats
Eloxx Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Eloxx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Eloxx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Eloxx Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 16, 2021: Eloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update
May 06, 2021: Eloxx Pharmaceuticals Reports First Quarter 2021 Financial and Operating Results and Provides Business Update
Mar 11, 2021: Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operating Results and Provides Business Update
Mar 04, 2021: Eloxx Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021
Nov 05, 2020: Eloxx Pharmaceuticals reports third quarter 2020 financial and operating results and provides business update
Sep 14, 2020: Globally renowned cystic fibrosis expert, Dr. Eitan Kerem, joins Eloxx Pharmaceuticals as a senior consultant
Aug 06, 2020: Eloxx Pharmaceuticals reports second quarter 2020 financial and operating results and provides business update
May 07, 2020: Eloxx Pharmaceuticals reports first quarter 2020 financial and operating results and provides business update
Apr 13, 2020: Eloxx Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Business Update on May 7, 2020
Mar 05, 2020: Eloxx Pharmaceuticals reports fourth quarter and full year 2019 financial and operating results and provides business update

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Eloxx Pharmaceuticals Inc, Key Facts
Eloxx Pharmaceuticals Inc, Key Employees
Eloxx Pharmaceuticals Inc, Key Employee Biographies
Eloxx Pharmaceuticals Inc, Major Products and Services
Eloxx Pharmaceuticals Inc, History
Eloxx Pharmaceuticals Inc, Subsidiaries
Eloxx Pharmaceuticals Inc, Key Competitors
Eloxx Pharmaceuticals Inc, Ratios based on current share price
Eloxx Pharmaceuticals Inc, Annual Ratios
Eloxx Pharmaceuticals Inc, Annual Ratios (Cont...1)
Eloxx Pharmaceuticals Inc, Interim Ratios
Eloxx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Eloxx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Eloxx Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Eloxx Pharmaceuticals Inc, Performance Chart (2016 - 2020)
Eloxx Pharmaceuticals Inc, Ratio Charts
Eloxx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Eloxx Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021